Experts are providing guidance on the use of capivasertib in treating hr-positive/her2-negative advanced breast cancer. The focus includes optimizing clinical monitoring and management, as well as strategies for safe use and combination with other treatments like fulvestrant. Research and studies, including phase 3 trials, are also being conducted to further understand the effectiveness of capivasertib in this context.